Select Medical Holdings Corporation (SEM) es una organización sanitaria con sede en EE. UU. que gestiona una cartera diversa de centros médicos ...
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
BPA est. $0.25 · Ingresos $1.42B · 3 analistas
BPA est. $1.22 · Ingresos $5.70B · 4 analistas
BPA est. $0.45 · Ingresos $1.48B · 1 analistas
BPA est. $0.33 · Ingresos $1.47B · 1 analistas
$0.25 por acción
$0.25 por acción
| Métrica | Último | InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo. | TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo. |
|---|---|---|---|
| IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores). | $5.5B | +5.1% | +1.8% |
| Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día. | $146.2M | -31.7% | +118.1% |
| Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión. | +11.5% | -5.5% | +57.3% |
| Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas). | +6.1% | +18.6% | +51.2% |
| Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas. | +2.7% | -35.0% | +114.3% |
| Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones. | $382.7M | -29.1% | -1167.9% |
| Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero. | +7.0% | -32.5% | -1149.2% |
| Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro. | 217.2% | +35.0% | -21.6% |
| Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico. | 1.04x | -0.2% | +10.0% |
| Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo. | $5.9B | +4.3% | +3.3% |
| Métrica | Anual (real vs estimado) | Sorpresa anual | Trimestral (real vs estimado) | Sorpresa trimestral |
|---|---|---|---|---|
| EPS Surprise | 1.18 vs 1.23 | -4.0% | 0.36 vs 0.25 | +41.3% |
| Revenue Surprise | $5.5B vs $5.4B | +0.6% | $1.4B vs $1.4B | +0.1% |
| Fecha | Ejecutivo | Cargo | Valor | Lado | Acciones | Precio |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Scully Thomas | director | Common Stock | D | 103,424 | $16.50 |
| Jun 30, 2026 | Davisson Katherine R | director | Common Stock | D | 60,035 | $16.50 |
| Jun 30, 2026 | Frist William H. | director | Common Stock | D | 306,266 | $16.50 |
| Jun 30, 2026 | TAVENNER MARILYN B | director | Common Stock | D | 36,035 | $16.50 |
| Jun 30, 2026 | Thomas Daniel | director | Common Stock | D | 80,035 | $16.50 |
Operator: Good morning, and thank you for joining us today for Select Medical Holdings Corporation's earnings conference call to discuss the first quarter 2026 results and the company's business outlook. Presenting today are the company's Chief Executive Officer, Thomas Mullin; and the company's Executive Vice President and Chief Financial Officer, Michael Malatesta. Also on the conference line is the company's Senior Vice President, Controller and Chief Accounting Officer, Christopher Weigl. Management will give you an overview of the quarter and then open the call for questions. Before we get started, we would like to remind you that this conference call may contain forward-looking statements regarding future events or the future financial performance of the company, including, without limitation, statements regarding operating results, growth opportunities and other statements that refer to Select Medical's plans, expectations, strategies, intentions and beliefs. These forward-looking statements are based on the information available to management of Select Medical today, and the company assumes no obligation to update these statements as circumstances change. At this time, I will turn the conference over to Mr. Thomas Mullin. Please go ahead. Thomas Mullin: Thank you, operator, and good morning, everyone. Welcome to Select Medical's earnings call for the first quarter of 2026. I'd like to begin today's call with a brief update on our previously announced take-private transaction. On March 2, we announced that Select Medical entered into an agreement to be acquired by a consortium led by our Executive Chairman, Robert Ortenzio, together with Martin Jackson and Welsh, Carson, Anderson & Stowe. Under the terms of the agreement, unaffiliated shareholders will receive $16.50 per share in cash. The transaction was unanimously approved by the disinterested members of the Board of Directors, and we expect it to close in mid-2026, subject to regulatory approvals, shareholder approval and other customary closing conditions. As part of the regulatory review process, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on April 27, satisfying one of these conditions. Upon closing, Select Medical will become a privately held company. In connection with and contingent upon the completion of the transaction, our senior secured credit facilities will provide for an additional $1 billion of term loan borrowings, bearing interest at a rate equal to SOFR plus 3%. With that update, I'll now turn to our development activity, where we continue to focus on expanding our inpatient rehabilitation business. So far this year, we've added 166 beds across 3 newly opened inpatient rehabilitation hospitals, including our fifth hospital with Baylor Scott & White Medical Center in Temple, Texas; a new hospital with CoxHealth in Ozark, Missouri and the fourth hospital in our Banner Health joint venture in Tucson, Arizona. Across the remainder of …
| Nombre | Cargo | Remuneración | Género | Año de nacimiento | Estado |
|---|---|---|---|---|---|
Robert A. Ortenzio | Cofundador y Presidente Ejecutivo | USD 3,053,469 | Male | 1958 | Active |
Martin F. Jackson | Vicepresidente Ejecutivo Sénior de Finanzas Estratégicas y Operaciones | USD 1,873,691 | Male | 1955 | Active |
Thomas Mullin | Director Ejecutivo | USD 1,617,527 | Male | 1984 | Active |
John A. Saich | Presidente | USD 1,610,527 | Male | 1969 | Active |
Michael F. Malatesta | Vicepresidente Ejecutivo y Director Financiero | USD 1,512,597 | Male | 1970 | Active |
Robert G. Breighner Jr. | Vicepresidente Sénior de Cumplimiento y Auditoría | — | Male | 1969 | Active |
Bridget Sherick | Vicepresidente Sénior de Contabilidad para Servicios Compartidos | — | — | — | Active |
Brian R. Rusignuolo | Vicepresidente Ejecutivo y Director de Información | — | Male | 1976 | Active |
Christopher S. Weigl | Vicepresidente Sénior, Contralor y Director de Contabilidad | — | Male | 1984 | Active |
John Duggan | Vicepresidente Ejecutivo, Asesor Jurídico General y Secretario | — | Male | 1964 | Active |
MECHANICSBURG, Pa., June 30, 2026 /PRNewswire/ -- Select Medical Holdings Corporation (the "Company" or "Select Medical," "we," "us," or "our") (NYSE: SEM) today announced the completion of its acquisition by an entity affiliated with a consortium led by Robert A.
MECHANICSBURG, Pa., June 26, 2026 /PRNewswire/ -- Select Medical Holdings Corporation (NYSE: SEM) ("Select Medical," "we," "us," or "our") confirmed today that its previously announced Agreement and Plan of Merger (the "Merger Agreement," and the transaction contemplated thereby, the "Merger") with an entity affiliated with a consortium led by Robert A.
NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Select Medical Holdings Corporation's (NYSE: SEM) board of directors and senior management for potential breaches of their fiduciary duties to shareholders in connection with the pending sale of the company for $16.50 per share as announced on March 2, 2026. If you are a current shareholder of Select Medical, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/select-medical-merger-lawsuit Why is Select Medical being Investigated?
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Select Medical Holdings Corporation's (NYSE: SEM) board of directors and senior management for potential breaches of their fiduciary duties to shareholders in connection with the pending sale of the company for $16.50 per share as announced on March 2, 2026. If you are a current shareholder of Select Medical, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/select-medical-merger-lawsuit Why is Select Medical being Investigated?
/PRNewswire/ -- Halper Sadeh LLC, un bufete de abogados de derechos de inversionistas, está investigando las siguientes compañías por posibles violaciones de las leyes federales de valores
